Da schau her, die News trudeln ein, sind schnell die letzten Wochen von 2 auf fast 4 Dollar.
Boston Biomedica Awarded Tenth US Patent for Pressure Cycling Technology (PCT)
WEDNESDAY, JUNE 04, 2003 9:48 AM
- PR Newswire
WEST BRIDGEWATER, Mass., Jun 04, 2003 /PRNewswire-FirstCall via Comtex/ -- Boston Biomedica, Inc. (BBII) today announced that the United States Patent and Trademark Office has issued Patent No. 6,569,672 to the Company for the design and use of its "Pressure Cycling Reactor" for the control of pressure sensitive reactions. This patent is an extension of previous Pressure Cycling Technology ("PCT") patents awarded to Boston Biomedica. PCT uses pulses of high pressure to reversibly turn on and off enzymatic reactions under very well defined and controlled conditions. The new patent describes a pressure cycling apparatus in which movement of fluids in and out of the reaction chamber can be precisely regulated by a series of valves under pressurized conditions. Such an enhancement would promote the study of protein-protein interactions, as it could both allow reagents to be added during a reaction, as well as allow the sampling of products from the reaction mixture, all under controlled pressure and temperature conditions.
This is the tenth patent issued to BBI for Pressure Cycling Technology. Previously issued patents included the instrumentation and methods needed to carry out the PCT process, with applications in extracting nucleic acids and proteins from cells and tissues, inactivation of viruses in plasma while retaining its therapeutic properties, purification of proteins and nucleic acids, DNA sequencing, and control of nucleic acid hybridizations.
"PCT is a novel, platform-based technology as evidenced by the continued expansion of our patent estate into additional applications," said Kevin Quinlan, President and Chief Operations Officer of Boston Biomedica. "This new patent represents another tool for the control of enzymatic reactions and may have future applications in diagnostics, therapeutics, and other areas of life sciences. We are currently seeking partners to help exploit these additional applications. Meanwhile, we will continue our current focus on the use of PCT for the extraction of nucleic acids, proteins, and small molecules from difficult-to-lyse tissues and cells, as we and our collaborators find new applications and advantages for this system in sample preparation."
About Boston Biomedica, Inc.
BBI provides products and services to the diagnostics and life sciences industries to evaluate, monitor, and ensure the quality of infectious disease test results, to improve the preparation of specimens for genomic/proteomic testing, and to safely store and retrieve rare and valuable biological specimens. We also manufacture reagents used in test kits and provide a broad range of routine and esoteric research services to governments and industry. BBI has facilities in three states, and conducts research in new applications for our patented Pressure Cycling Technology (PCT). In 2000, we launched Panacos Pharmaceuticals, and the Company maintains a significant passive investment in this novel antiviral drug development company.
Forward Looking Statement
Statements contained in this news release that state the Company's or management's intention, hopes, beliefs, expectations or predictions of the future are "forward-looking" statements. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. Factors that could cause actual results to differ from those projected include the possibility that PCT may not become a cost- effective method for regulating biomolecules; that, due to difficulties in the development of the technology, BBI may not be successful in developing pressure cycling technology into commercially viable products or services; that pressure cycling technology may not be adaptable to any other commercially viable applications; that certain pressure cycling applications may not fall within the claims of the Company's ten issued patents; that the Company may not succeed in finding partners to help exploit PCT, and that individuals and groups utilizing such PCT procedures may not be required to license such technology from BBI. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained from time to time in the Company's SEC filings, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2002 and the Company's Quarterly Reports on Form 10-Q for the three months ended March 31, 2003. Copies of these documents may be obtained by contacting the Company or the SEC.
Visit us at our website www.bbii.com
